9–18 However, although these gene expression signatures might better reflect the biological characteristics of HCC tumors, the complexity of prediction models based on such signatures has hampered their clinical usefulness. To overcome this Gefitinib purchase limitation, we developed a simple risk scoring system that can predict overall survival (OS) of patients after surgical resection for HCC. AUC, area under the curve; BCLC, Barcelona-Clinic Liver Cancer; GEO, Gene Expression Omnibus; HBsAg, HBV surface antigen; HBV, hepatitis B virus; HCC, hepatocellular carcinoma; INSERM, Institute for Health and Medical Research; LCI, Liver Cancer Institute;
LOOCV, leave-one-out-cross-validation; MSH, Mount Sinai Hospital; NCBI, National Center for Biotechnology Information; NCI, National Cancer Institute; OS, overall survival; ROC, receiver-operating characteristic. Gene expression and clinical data from the National Cancer Institute (NCI), Mount Sinai Hospital (MSH), and Liver Cancer Institute (LCI) HCC cohorts, as reported in previous studies, were acquired from the National Center for Biotechnology Information (NCBI) Gene Expression
Omnibus (GEO) database (accession numbers GSE1898, GSE4024, GSE9843, and GSE14520).11, 13, 15–17 Gene expression data from HCC patients at the French National Institute for Health and Medical Research (INSERM) were obtained from ArrayExpress, another public microarray database (accession number E-TABM-36).9 In addition to these gene expression data from previous studies, we included http://www.selleckchem.com/products/XL184.html gene expression data from 100 patients with HCC (the Korean cohort) as an independent validation cohort for the risk score. Tumor specimens MCE and clinical data were obtained from HCC patients undergoing hepatectomy as primary treatment for HCC at Seoul National University, Seoul, and Chonbuk National University, Jeonju, Korea. One hundred surgically removed frozen HCC specimens were used for microarray experiments. Samples were frozen in liquid nitrogen and stored at −80°C until RNA extraction. The study
protocols were approved by the Institutional Review Boards at both institutions, and all participants provided written, informed consent. Gene expression data from the Korean cohort were generated using the Illumina microarray platform (Illumina, San Diego, CA). Patients in the Korean cohort were followed up prospectively at least once every 3 months after surgery. Most of the patients in the two validation cohorts were men (83% for Korean cohort and 87.5% for LCI cohort), Child-Pugh class A (92% for Korean cohort and 87% for LCI cohort), and had cirrhosis (64% for Korean cohort and 92.0% for LCI cohort). Hepatitis B virus (HBV) infection was determined by serological positivity for HBV surface antigen (HBsAg) or anti-HBe antibodies.